Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RLY-5836 |
Synonyms | |
Therapy Description |
RLY-5836 is a mutant-selective PIK3CA inhibitor, which potentially induces apoptosis and inhibits growth of tumor cells expressing mutant PIK3CA (Cancer Res (2024) 84 (9_Supplement): PO3-20-04, NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RLY-5836 | RLY 5836|RLY5836 | PIK3CA inhibitor 25 | RLY-5836 is a mutant-selective PIK3CA inhibitor, which potentially induces apoptosis and inhibits growth of tumor cells expressing mutant PIK3CA (Cancer Res (2024) 84 (9_Supplement): PO3-20-04, NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05759949 | Phase I | Fulvestrant + RLY-5836 RLY-5836 Fulvestrant + Palbociclib + RLY-5836 Abemaciclib + Fulvestrant + RLY-5836 Fulvestrant + Ribociclib + RLY-5836 | First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors | Active, not recruiting | USA | 0 |